CDH2 and head and neck squamous cell carcinoma: Indirect immunofluorescence was also performed to verify the upregulation of EMT markers N-cadherin (Figure 2C and Figure S2E) and Vimentin (Figure 2D) in IL-6-treated HNSCC cells and their downregulation when treated with tocilizumab.